摘要
目的:了解2013–2017年我国七城市降胆固醇药物的应用情况,为临床合理用药提供参考。方法:随机抽取七城市95家医院的处方信息,对销售金额、用药频度、他汀强度等进行统计分析。结果:共纳入680.20万张处方,累计消耗7.77亿元。患者男女比例为1.26∶1,75岁以下与75岁以上比例为2.10∶1,分别有28.23%、11.21%、27.71%的患者合并高血压、糖尿病及动脉粥样硬化性心血管疾病。阿托伐他汀的销售金额及用药频度均稳居第一,分别占51.47%及45.54%。瑞舒伐他汀紧随其后,销售金额及用药频度分别占26.64%及28.00%。各地区瑞舒伐他汀的日均费用均明显低于阿托伐他汀,平均相差1.35元。65.91%的他汀疗法为中等强度,高强度仅占5.73%。北京地区高强度他汀(12.99%)比例明显高于其他城市。非他汀类药物占比低,但天津地区普罗布考的使用率相对较高(11.92%)。结论:我国七城市降胆固醇药物以阿托伐他汀和瑞舒伐他汀为主,其中瑞舒伐他汀可能具有价格优势,中等强度他汀是主要治疗选择。
Objective: To evaluate the utilization of anticholesteremic agents in seven cities of China from 2013 to 2017 in order to provide references for rational drug use. Methods: Prescriptions for high cholesterol were randomly selected from 95 hospitals in seven cities. Prescription information including sales sum, prescription amount and statin intensity was statistically analyzed. Results: A total of 6.80 million prescriptions were included. The sales sum was 0.78 billion yuan. The ratio of male to female was 1.26 : 1. The ratio of patients under 75 years old and over 75 years old was 2.10 : 1. Percentage of patients with hypertension, diabetes and atherosclerotic cardiovascular disease was 28.23%, 11.21% and 27.71%, respectively. The sales sum and medication frequency of atorvastatin were 51.47% and 45.54%, which were both ranked first. The followed was rosuvastatin. The sales sum and medication frequency of rosuvastatin were 26.64% and 28.00%. The daily average cost of rosuvastatin was significantly lower than that of atorvastatin with an average difference of 1.35 yuan. 65.91% of statin therapy was moderate-intensity while only 5.73% of statin therapy was high-intensity. The proportion of high-intensity statins in Beijing (12.99%) was significantly higher than that of other cities. The proportion of non-statin therapy was low except probucol in Tianjin (11.92%). Conclusion: Atorvastatin and rosuvastatin were the top two anticholesteremic agents used in the above seven cities of China. Rosuvastatin might be prior to atorvastatin according to price. Moderate-intensity statins were the primary treatment option.
作者
方振威
石秀锦
石佳
林阳
FANG Zhen-wei;SHI Xiu-jin;SHI Jia;LIN Yang(Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China)
出处
《中国药物应用与监测》
CAS
2019年第2期96-100,共5页
Chinese Journal of Drug Application and Monitoring
基金
北京市医院管理局临床医学发展专项经费资助项目(ZYLX201805)
关键词
降胆固醇药物
他汀
用药分析
Anticholesteremic agents
Statin
Utilization analysis
